Company intelligence / Profile preview

Angel Pharmaceuticals

Jiaxing, Zhejiang, Chinaangelpharma.com ↗

Ownership: Private
Development stage: Phase 3

Overview

CPI-818 (soquelitinib) has been approved by the FDA to enter Phase 3 clinical trials for relapsed/refractory peripheral T cell lymphoma. Preliminary results have shown tumor responses in advanced, refractory T cell malignancies. CPI-006 (mupadolimab) is in clinical trials for non-small cell lung cancer and has shown impressive efficacy data. ANG-0623 has obtained Phase 1 clinical trial approvals from the U.S. FDA and China CDE for multiple sclerosis treatment[1][5][9].

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Small moleculesMonoclonal antibodies
Industry: Biotech

Drug pipeline

2 assets

PARP7 inhibitor

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Corvus Pharmaceuticals, Inc. (strategic collaboration)

Beyond the preview

Go deeper on Angel Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angel Pharmaceuticals.

Explore the full profile